We read with great interest the SWEDEHEART report by Tjerkaski et al. 1 regarding the
comparison of ticagrelor vs. clopidogrel in patients with myocardial infarction (MI) and high …

Dual antiplatelet therapy (DAPT) has been the mainstay treatment to reduce ischemic
events, such as myocardial infarction or stroke, in patients with coronary artery disease …

Aims To establish the safety and efficacy of different dual antiplatelet therapy (DAPT)
combinations in patients with acute coronary syndrome (ACS) according to their baseline …

Aim Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary
intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and …

INTRODUCTION: Type 2 diabetes mellitus (T2DM) patients have a variable response profile
to the P2Y12 receptor antagonist clopidogrel. P2Y12 receptor signalling promotes platelet …

Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …

Percutaneous coronary intervention is widely used to reduce the risk of death or
cardiovascular events in patients with acute coronary syndromes. Dual antiplatelet treatment …

What is known and objective Patients with type 2 diabetes mellitus (T2DM) are at higher risk
of thrombotic complications. Studies have indicated that patients with T2DM have impaired …

Antiplatelet therapy is essential to reduce athero-thrombotic events in patients undergoing
percutaneous coronary intervention (PCI), but this strategy is inevitably associated with an …